The court ruled in favor of the patients in a damages lawsuit filed by 139 patients who received the osteoarthritis treatment drug Invossa K (Invossa). This is the first trial ruling that came about seven years after the lawsuit was filed in 2019. Invossa was approved as Korea's first gene therapy, but the approval was canceled when it was revealed that the main ingredient had been changed. Attorney Eom Tae-seop said on June 23, 2019 at the Daegu Chamber of Commerce and Industry in Dong-gu, Daegu, that Invossa blood...